N-[2-[[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]thio]ethyl]-1,2,5-thiadiazole-3,4-diamine1-oxide

BMY-25271 is a histamine H2 receptor antagonist.

BMY-25271 is a histamine H2 receptor antagonist.

BMY-25271 is a histamine H2 receptor antagonist. The dose response curves are parallel and oral ED ₅₀ values derived from probit analysis are 0.093, 0.97 and 6.9 mg/kg for BMY- 25271, ranitidine and cimetidine, respectively. Therefore it is about 10 and 74 times more potent than ranitidine and cimetidine, respectively.

H₂ Receptor

[1] Cavanagh RL, et al. Prevention of aspirin-induced gastric mucosal injury by histamine H2 receptor antagonists: a crossover endoscopic and intragastric pH study in the dog. J Pharmacol Exp Ther. 1987 Dec;243(3):1179-84. PMID:2891837